To determine the efficacy of ornithine-aspartate in reducing blood ammonia levels and clinical improvement, as a part of treatment in hepatic encephalopathy. Material & method: A randomized placebo controlled trial was conducted in 2013 in Jinnah medical and dental college hospital Korangi Karachi. One hundred patients with hepatic encephalopathy due to underlying chronic liver disease were randomly assigned into two groups with 50 patients each. One group received three days of ornithine-aspartate infusions (trial-treatment group) and the other group received three days of infusion of placebo (placebo group). Serum ammonia was measured in both groups on day 1 and day 3. Clinical improvement was assessed by West Haven’s grading of hepatic encephalopathy. Result: The patients in trial group showed statistically significant improvement in serum ammonia levels and grading of hepatic encephalopathy as compared to placebo. Conclusion: L -Ornithinie L-Aspartate (LOLA) is effective in decreasing serum ammonia as well as results in clinical improvement in patients with hepatic encephalopathy and may be recommended for use in hepatic encephalopathy.
Aidrus, Fadieleh; Razzaque, Salma; Siddiqui, Afshan; Kumar, Ajeet; and Ghaur, M. Ishaq
"Therapeutic efficacy of l-ornithine l-aspartate in patients with hepatic encephalopathy,"
Pakistan Journal of Neurological Sciences (PJNS): Vol. 10:
3, Article 9.
Available at: https://ecommons.aku.edu/pjns/vol10/iss3/9